Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

By sjmartinez • July 28, 2024

Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter KM, Camp HS, Rubbert-Roth A. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD Open. 2024 Jul 25;10(3):e003918. doi: 10.1136/rmdopen-2023-003918. PMID: 39059811; PMCID: PMC11284939.

Tags: Antirheumatic Agents, Publications, Rheumatoid arthritis, Rheumatology, Therapeutics

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Møller[...]

Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology

Tang HS, Ebriani J, Yan MJ, Wongvibulsin S, Farshchian M. Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology.[...]

Author Correction: Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice

Özcan E, Yu KB, Dinh L, Lum GR, Lau K, Hsu J, Arino M, Paramo J, Lopez-Romero A, Hsiao EY. Author Correction: Dietary fiber content[...]